Oral PCSK9 Inhibitors: Current Clinical Development
There is no FDA-approved oral PCSK9 inhibitor currently available, but several are in active clinical development, with MK-0616 being the most advanced candidate showing robust LDL-C reductions of up to 60.9% in Phase 2b trials.
Leading Oral PCSK9 Inhibitor Candidates
MK-0616 (Most Advanced)
MK-0616 is an oral macrocyclic peptide PCSK9 inhibitor that has completed Phase 2b trials and is advancing to Phase 3 1. In a randomized trial of 381 participants with hypercholesterolemia:
- Demonstrated dose-dependent LDL-C reductions ranging from 41.2% (6 mg) to 60.9% (30 mg) at 8 weeks 1
- Well-tolerated profile with adverse events occurring in similar proportions to placebo (39.5-43.4% vs 44.0%) 1
- Minimal discontinuations due to adverse events (≤2 participants per treatment group) 1
- Uses innovative synthetic chemistry and mRNA display technology to create a larger peptide that covers more of the PCSK9 protein surface compared to smaller linear peptides 2
Other Oral PCSK9 Inhibitors in Development
Recent meta-analyses have identified additional oral PCSK9 inhibitors in clinical trials 3, 4:
- Enlicitide - Currently in development with promising Phase 3 data 5
- NNC0385-0434 - In clinical trials 3
- Laroprovstat - Under investigation 3
Efficacy Across Oral PCSK9 Inhibitor Class
Pooled analysis of 5 randomized controlled trials (3,295 participants) demonstrates that oral PCSK9 inhibitors as a class achieve 3:
- LDL-C reduction: -59.31% (95% CI -62.33 to -56.28)
- Apolipoprotein B reduction: -49.53% (95% CI -54.19 to -44.79)
- Non-HDL cholesterol reduction: -55.41% (95% CI -57.35 to -53.48)
- Lipoprotein(a) reduction: -22.74% (95% CI -26.67 to -18.81)
These reductions are comparable to injectable PCSK9 inhibitors (evolocumab and alirocumab) but offer the convenience of oral administration 6, 4.
Safety Profile
Across multiple meta-analyses, oral PCSK9 inhibitors show:
- No increased risk of serious adverse events compared to placebo (RR 0.84,95% CI 0.68-1.03) 3
- Similar overall adverse event rates to placebo 4, 7
- Short-term safety data (8-24 weeks) is reassuring, though long-term cardiovascular outcomes data are pending 3, 5
Clinical Context and Current Limitations
What's Missing
- No cardiovascular outcomes data yet - Unlike injectable PCSK9 inhibitors (evolocumab and alirocumab), which have proven cardiovascular risk reduction in FOURIER and other trials 8, oral agents lack long-term outcomes data 6, 5
- Limited duration of exposure - Current trials range from 8-24 weeks; longer-term safety and efficacy remain to be established 3
- No FDA approval - All oral PCSK9 inhibitors remain investigational
Potential Advantages Over Injectable PCSK9 Inhibitors
- Improved adherence - Oral administration may enhance long-term compliance compared to subcutaneous injections 6
- Patient preference - More convenient dosing without injection-related barriers 2
- Comparable efficacy - LDL-C lowering appears similar to injectable agents 3, 4
Current Clinical Guideline Context
Important caveat: Current guidelines 9, 8 only address injectable PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), as oral agents were not available when these were published. The 2022 BMJ guideline suggests:
- Adding PCSK9 inhibitors for patients at very high and high cardiovascular risk already on maximum statin therapy 9
- Ezetimibe is preferred over PCSK9 inhibitors as the second lipid-lowering agent due to cost considerations 9
- PCSK9 inhibitors may be added to ezetimibe in very high-risk patients 9
These recommendations will likely need revision once oral PCSK9 inhibitors complete Phase 3 trials and cardiovascular outcomes studies.
Bottom Line
MK-0616 is the leading oral PCSK9 inhibitor in clinical development, currently in Phase 3 trials, with Phase 2b data showing LDL-C reductions comparable to injectable PCSK9 inhibitors and a favorable safety profile 1, 2. Other oral agents (enlicitide, NNC0385-0434, laroprovstat) are also being investigated 3. While these agents show promise for improving treatment accessibility and adherence, they remain investigational and lack the cardiovascular outcomes data that support current injectable PCSK9 inhibitors 6, 5.